Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wnt5A siRNA
- Development stage
- Preclinical
- Lead developer
- The Wistar Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
Wnt5A siRNA is a research-stage small interfering RNA (siRNA) designed to silence the expression of the *WNT5A* gene. Wnt5a is a highly conserved ligand that activates the non-canonical Wnt signaling pathway, which is implicated in various pathological processes including tumor progression, metastasis, and inflammatory diseases. In oncology, Wnt5a has been identified as a driver of enzalutamide resistance in prostate cancer and therapeutic resistance in melanoma. Preclinical studies have utilized various delivery vehicles, such as bioengineered RNA agents (BERA) or adenoviral vectors, to evaluate the therapeutic potential of Wnt5a knockdown in models of advanced prostate cancer, melanoma, and atherosclerosis.
- Other names
- Wnt5a-targeting siRNAWnt-5a-targeting siRNAWnt 5a-targeting siRNAsiRNA targeting WNT5A
02
Targets
WNT5A (Protein Wnt-5a)
Beyond the preview
Go deeper on Wnt5A siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wnt5A siRNA.